Physician profile
John J Scheibelhoffer
NPI 1194764712
$3,609.88
in general payments reported to CMS, 2019-2025
27 companies · $934 in 2025
The $934 reported for 2025 was more than what 84% of Facial Plastic Surgery providers received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $70.23 · 2021: $132 · 2022: $562 · 2023: $880 · 2024: $843 · 2025: $934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,656.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $951.07 | 2022-2025 | |
| Glaxosmithkline, LLC. | $498.17 | 2019-2025 | Nucala |
| Optinose US, INC. | $362.95 | 2019-2025 | |
| Aerin Medical INC. | $332.93 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $289.60 | 2019-2025 | Dupixent |
| Csl Behring | $269.66 | 2022-2025 | Haegarda, Hizentra, Andembry |
| Kaleo, INC. | $228.86 | 2022-2024 | Auvi-Q |
| Stryker Corporation | $98.96 | 2019-2020 | |
| Alk-Abello, INC | $72.52 | 2019-2023 | Grastek, Odactra, Ragwitek |
| Takeda Pharmaceuticals U.S.A., INC. | $63.92 | 2021-2024 | Eohilia, Takhzyro |
| Merck Sharp & Dohme LLC | $51.08 | 2021-2023 | Verquvo |
| Blueprint Medicines Corporation | $38.06 | 2023-2025 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $34.19 | 2025 | |
| Aytu Biopharma, INC. | $33.20 | 2025 | |
| Leo Pharma INC. | $29.98 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $29.92 | 2023 | Ryaltris |
| Olympus America INC. | $29.87 | 2019 | |
| Pharming Healthcare, INC. | $29.22 | 2019-2025 | Ruconest |
| Medtronic, INC. | $26.14 | 2025 | Propel |
| Intersect Ent, INC. | $24.40 | 2020 | |
| Biocryst US Sales Co., LLC | $20.02 | 2025 | |
| Phathom Pharmaceuticals, INC. | $18.98 | 2025 | Voquezna |
| Phadia US INC. | $18.77 | 2022 | |
| Ionis Pharmaceuticals, INC. | $17.75 | 2025 | Dawnzera |
| Aimmune Therapeutics, INC. | $15.47 | 2022 | |
| Incyte Corporation | $15.19 | 2022 | |
| Glenmark Therapeutics INC. | $9.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Scheibelhoffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.